Influencing CYP Enzymes to Boost Psychiatric Treatment: A Review on Clinical Evidencevan Hasselt, F. M., Coehorst, Y., Wilffert, B. & Loonen, A. J. M., Mar-2013, In : Pharmacopsychiatry. 46, 2, p. 43-46 4 p.
Research output: Contribution to journal › Review article › Academic › peer-review
Introduction: Therapeutic drug monitoring to optimize blood plasma concentrations is advised for certain psychiatric drugs. The current standard is to change the dose based on the blood plasma concentration. We present an overview that blood plasma concentrations can also be influenced by adding co-medication based on pharmacokinetic knowledge.
Method: We performed a systematic review in medical databases for pharmaco-enhancing strategies, and we present 2 cases on actively influencing CYP3A4 metabolism.
Results: 4 original studies were selected on strategies to influence CYP metabolism. 2 studies on influencing CYP2D6 metabolism, 2 studies on influencing CYP1A2 metabolism. In all studies an effect of this influence was present.
Discussion: Ample clinical evidence is present, but shows promising results. Pharmacokinetic knowledge can and should be used in clinical settings to optimize pharmacotherapy for vulnerable patients. Also the access to expensive medication can be increased by reduction of high dosage schemes.
|Number of pages||4|
|Publication status||Published - Mar-2013|
- mental disorders, drug therapy, Cytochrome P-450 CYP3A, DRUG-DRUG INTERACTIONS, ATYPICAL ANTIPSYCHOTICS, PHARMACOKINETICS, QUETIAPINE, METABOLISM